Business |
S&P edges closer to record high; energy
shares lead
DJ: 17,938.28 +17.95 NAS: 4,961.75 -6.96 S&P: 2,112.13
+2.72
(Reuters) The
S&P 500 ended at its best level since July on Tuesday, helped by a big jump
in energy shares and investor confidence that higher interest rates will not
derail the economy. The index finished below its best
levels of the session, though, while the Nasdaq ended lower. Biotech shares
dropped following disappointing news from several key companies including
Biogen. The Nasdaq Biotech Index .NBI was down 2.5 percent, its biggest daily
percentage decline since May 11.
Giving the S&P 500 its biggest boost, the S&P energy
index .SPNY jumped 2.1 percent as oil prices reached 2016 highs due to supply
constraints and a weak dollar. Exxon Mobil (XOM.N)
gained 1.5 percent to $90.71.
Gains this week have once
again put the S&P 500 within striking distance of record highs reached in
May 2015. Comments from Fed Chair Janet Yellen on Monday seemed to ease some
worries about the economy, while underscoring views the Fed may be in no rush
to raise rates.
"The big story for the market right now is, do we break out to all-time
highs," said Michael Sheldon, chief investment officer at Northstar
Wealth Partners in West Hartford, Connecticut.
"If we do so in the near term, we could see a rush of money
jump into the market from investors who had been sitting out on the sidelines,
in fear missing out on further market gains."
The Dow Jones industrial
average .DJI ended up 17.95 points, or 0.1 percent,
to 17,938.28, and earlier broke above 18,000, while the S&P 500 .SPX gained 2.72 points, or 0.13 percent, to
2,112.13, its highest close since July 22.
The benchmark index now sits less than 19 points from its all-time
closing high of 2130.82. The Nasdaq
Composite .IXIC dipped 6.96 points, or 0.14 percent, to
4,961.75.
Navistar International (NAV.N)
shares jumped 19.6 percent to $14.54 after it posted a surprise second-quarter
profit.
On the downside, the S&P 500 healthcare index .SPXHC dropped
0.7 percent, dragged down by Biogen (BIIB.O) and
Alexion (ALXN.O).
Biogen tumbled 12.8 percent to $252.86 after its multiple
sclerosis drug failed in a mid-stage study.
Alexion dropped 10.9 percent to $138.13 after its drug failed a
trial, while Valeant (VRX.N)
slumped 14.6 percent to $24.64 after the drugmaker cut its full-year forecast.
About 6.4
billion shares changed hands on U.S. exchanges, below the 6.9 billion
daily average for the past 20 trading days, according to Thomson Reuters data.
Advancing issues outnumbered declining ones on the NYSE by 1,896
to 1,136, for a 1.67-to-1 ratio on the upside; on the Nasdaq, 1,462 issues rose
and 1,364 fell for a 1.07-to-1 ratio favoring advancers.
The S&P 500 posted 43 new 52-week highs and one new low; the
Nasdaq recorded 82 new highs and 22 new lows.
No comments:
Post a Comment